Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

• Status: Completed
• Trial end date: 2015-07-01

Summary

Non-treatment extension to study A3051123, aimed at collecting data on cardiovascular safety for all participants in the A3051123 trial for an additional 28 weeks, allowing for a total of 52 weeks of cardiovascular safety data collection.

• Phase: Phase 4

Details

• Lead Sponsor: Pfizer
• Treatments: Bupropion; Nicotine; Varenicline